Caring Brands, Inc. (NASDAQ:CABR) Short Interest Down 48.5% in July

Caring Brands, Inc. (NASDAQ:CABR) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 36,455 shares, a drop of 48.5% from the June 30th total of 70,819 shares. Based on an average daily trading volume, of 85,145 shares, the short-interest ratio is presently 0.4 days. Approximately 0.5% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Caring Brands Stock Up 3.3%

Shares of CABR stock traded up $0.05 during mid-day trading on Wednesday, hitting $1.56. 37,258 shares of the company’s stock were exchanged, compared to its average volume of 107,810. The stock has a market capitalization of $14.18 million and a PE ratio of -2.44. The company has a current ratio of 5.66, a quick ratio of 5.62 and a debt-to-equity ratio of 0.03. Caring Brands has a fifty-two week low of $0.71 and a fifty-two week high of $5.35. The company has a 50-day simple moving average of $1.25.

Caring Brands (NASDAQ:CABR) last released its earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Institutional Trading of Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC acquired a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent reporting period.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.